Compugen Reports Second Quarter 2026 Results

Data ReadoutCOM701Positive

AI Analysis

Summary

Compugen reported Q2 2026 results with COM701 MAIA-ovarian trial progressing as planned. Median progression-free survival data from the interim analysis is expected by Q1 2027.

Clinical Trial Data

Outcome Details

Median progression-free survival data from MAIA-ovarian interim analysis expected by Q1 2027

Importance:5/10

Sentiment:

0.30

ovarian cancerMAIA-ovarian trialprogression-free survivalinterim analysisESMO Gynaecological Cancers Congress 2026

Related Companies

$CGEN

Read the original article

Published by PR Newswire Biotech on August 3, 2026 11:00 AM

Read Original